ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

LIXT Lixte Biotechnology Holdings Inc

2.40
-0.12 (-4.76%)
Jun 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,148,787
Bid Price 2.32
Ask Price 3.10
News (2)
Day High 3.50

Low
1.58

52 Week Range

High
9.50

Day Low 2.37
Company Name Stock Ticker Symbol Market Type
Lixte Biotechnology Holdings Inc LIXT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -4.76% 2.40 00:00:16
Open Price Low Price High Price Close Price Prev Close
2.51 2.37 3.50 2.45 2.52
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,353 1,148,787 $ 2.89 $ 3,322,273 - 1.58 - 9.50
Last Trade Time Type Quantity Stock Price Currency
19:56:43 formt 118 $ 2.40 USD

Lixte Biotechnology Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.51M 2.25M - 0 -5.09M -2.26 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Lixte Biotechnology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LIXT Message Board. Create One! See More Posts on LIXT Message Board See More Message Board Posts

Historical LIXT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.423.502.052.3220,006-0.02-0.83%
1 Month2.453.502.052.4929,405-0.05-2.04%
3 Months2.244.402.053.49587,4300.167.14%
6 Months2.054.401.693.41291,8950.3517.07%
1 Year5.159.501.583.80192,672-2.75-53.40%
3 Years30.5049.501.5817.39717,283-28.10-92.13%
5 Years38.5071.901.5821.69705,381-36.10-93.77%

Lixte Biotechnology Description

Lixte Biotech Holdings Inc is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company focuses on developing new treatments for human cancers for which therapies are urgently needed. It mainly designs drugs for which there are existing data suggesting any effect on altered pathways of the cancer cell and may be given safely to humans. The development program of the company includes drugs for the treatment of cancer, consisting of protein phosphatase inhibitors and histone deacetylase inhibitors.

Your Recent History

Delayed Upgrade Clock